OncoMatch/Clinical Trials/NCT07080216

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Is NCT07080216 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ZG005 and Bevacizumab for cervical cancer.

Phase 1/2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT07080216Data as of May 2026

Treatment: ZG005 · Gecacitinib · Bevacizumab — This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify